Nektar Therapeutics

NKTR

$59.58

Name : Nektar Therapeutics

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $1,211,951,872.00

EPSttm : -9.83

Nektar Therapeutics

$59.58

5.12%

$2.90

Float Short %

7.4

Margin Of Safety %

Put/Call OI Ratio

0.59

EPS Next Q Diff

-0.72

EPS Last/This Y

0.73

EPS This/Next Y

-3

Price

59.23

Target Price

93.86

Analyst Recom

1.67

Performance Q

122.98

Relative Volume

0.61

Beta

-0.98

Ticker: NKTR

21 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-10-20	NKTR	62.99	0.72	0.12	40454
2025-10-21	NKTR	59.37	0.66	0.10	43037
2025-10-22	NKTR	61.75	0.66	0.81	43379
2025-10-23	NKTR	63.66	0.63	1.85	42848
2025-10-24	NKTR	60.38	0.67	0.58	42960
2025-10-27	NKTR	62.43	0.70	0.06	43948
2025-10-28	NKTR	60.83	0.68	0.33	44439
2025-10-29	NKTR	59.52	0.68	0.42	45056
2025-10-30	NKTR	62.72	0.68	0.09	45017
2025-10-31	NKTR	64.82	0.68	0.11	45434
2025-11-03	NKTR	59.92	0.68	0.10	45579
2025-11-04	NKTR	56.01	0.68	0.35	45742
2025-11-05	NKTR	54.36	0.69	0.34	45895
2025-11-06	NKTR	55.13	0.69	0.50	45755
2025-11-07	NKTR	55.97	0.69	0.38	45685
2025-11-10	NKTR	57.96	0.65	0.03	46040
2025-11-11	NKTR	59.26	0.63	0.11	47072
2025-11-12	NKTR	57.66	0.63	0.59	47191
2025-11-13	NKTR	54.01	0.62	0.15	47517
2025-11-14	NKTR	56.67	0.60	0.26	49585
2025-11-17	NKTR	59.5	0.59	0.56	50308
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

21 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-10-20	NKTR	62.99	-5.5	-	-11.06
2025-10-21	NKTR	59.41	-5.5	-	-10.71
2025-10-22	NKTR	61.78	-5.5	-	-10.35
2025-10-23	NKTR	63.67	-5.5	-	-10.35
2025-10-24	NKTR	60.19	-5.1	-	-10.35
2025-10-27	NKTR	62.54	-5.1	-	-10.35
2025-10-28	NKTR	60.92	-5.1	-	-10.35
2025-10-29	NKTR	59.56	-5.1	-	-10.35
2025-10-30	NKTR	62.80	-5.1	-	-10.35
2025-10-31	NKTR	64.93	-5.1	-	-10.35
2025-11-03	NKTR	59.89	-5.1	-	-10.35
2025-11-04	NKTR	56.07	-5.1	-	-10.35
2025-11-05	NKTR	54.15	-5.1	-	-10.35
2025-11-06	NKTR	54.97	-5.1	-	-10.35
2025-11-07	NKTR	55.97	-5.1	-	-10.35
2025-11-10	NKTR	57.97	-32.2	-	-10.35
2025-11-11	NKTR	59.26	-32.2	-	-7.97
2025-11-12	NKTR	57.72	-32.2	-	-7.97
2025-11-13	NKTR	53.97	-32.2	-	-7.97
2025-11-14	NKTR	56.67	-32.2	-	-7.97
2025-11-17	NKTR	59.23	-32.2	-	-7.97
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-10-20	NKTR	-14.28	-1.34	10.60
2025-10-21	NKTR	-14.28	-1.34	10.60
2025-10-22	NKTR	-14.28	-1.34	10.60
2025-10-23	NKTR	-14.28	-1.34	10.60
2025-10-24	NKTR	-14.28	-1.34	10.60
2025-10-27	NKTR	-14.28	-1.56	9.31
2025-10-28	NKTR	-14.28	-1.56	9.31
2025-10-29	NKTR	-13.96	-1.56	9.32
2025-10-30	NKTR	-13.96	-1.56	9.32
2025-10-31	NKTR	-13.96	-1.56	9.32
2025-11-03	NKTR	-14.28	-4.30	9.31
2025-11-04	NKTR	-14.28	-4.30	9.31
2025-11-05	NKTR	-14.28	-4.30	9.31
2025-11-06	NKTR	-14.28	-4.30	9.31
2025-11-07	NKTR	-14.28	-4.30	9.31
2025-11-10	NKTR	-14.28	-0.16	9.31
2025-11-11	NKTR	-14.28	-0.16	9.31
2025-11-12	NKTR	-13.48	-0.16	0
2025-11-13	NKTR	-13.48	-0.16	7.40
2025-11-14	NKTR	-13.48	-0.16	7.40
2025-11-17	NKTR	-13.48	17.68	7.40
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

-1.87

Avg. EPS Est. Current Quarter

-2.98

Avg. EPS Est. Next Quarter

-2.59

Insider Transactions

-13.48

Institutional Transactions

17.68

Beta

-0.98

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

85.2

Max Drawdown 5-Year %

-98.3

Target Price

93.86

P/E

Forward P/E

PEG

P/S

19.36

P/B

13.76

P/Free Cash Flow

EPS

-7.94

Average EPS Est. Cur. Y

-7.97

EPS Next Y. (Est.)

-10.97

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-192.87

Relative Volume

0.61

Return on Equity vs Sector %

-168.9

Return on Equity vs Industry %

-153.9

EPS 1 7Days Diff

2.4

EPS 1 30Days Diff

3.09

EBIT Estimation

Nektar Therapeutics

Sector: Healthcare

Industry: Biotechnology

Employees: 61

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution processes of inflammation and has applications in a number of therapeutic indications, including acute and chronic inflammation; Tumor necrosis factor (TNF) receptor type II (TNFR2) agonist asset is a bivalent antibody molecule used to selectively stimulate TNFR2 receptor activity, without modulation of the TNFR1 signaling; and NKTR-255, an IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

stock quote shares NKTR – Nektar Therapeutics Stock Price stock today

news today NKTR – Nektar Therapeutics stock forecast ,stock prediction 2023 2024 2025

marketwatch NKTR – Nektar Therapeutics yahoo finance google finance

stock history NKTR – Nektar Therapeutics invest stock market

stock prices NKTR premarket after hours

ticker NKTR fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: NKTR

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y